Payment overview · 2025
General Payments
$789.50
34 reported records · 8 companies
Healthcare provider profile · identity verified
Varinder Jindal, FNP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Primary Care · BROOKLYN, NY · NPI 1558092221
Verified facts
What the public records show
CMS Open Payments records show Varinder Jindal, FNP-C received $789.50 in general payments during 2025 across 34 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 42.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Kerendia, Linzess, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trelegy Ellipta by this doctor in 2024.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Linzess by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $332.34 | 42.1% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $201.90 | 25.6% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $83.24 | 10.5% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $47.70 | 6.0% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $47.13 | 6.0% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $41.24 | 5.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.27 | 2.4% | 1 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $16.68 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $789.50 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $332.34 | 13 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $104.20 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $83.24 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $83.24 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $47.70 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $47.13 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $44.17 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $26.91 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $25.98 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| Linzess Normalized: linzess |
Drug | IRONWOOD PHARMACEUTICALS, INC | $16.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 89 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 54 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Linzess linzess |
2025 | Linzess | 2024 | 149 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 138 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
89 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
149 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
138 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Albuterol Sulfate Hfa | Albuterol Sulfate | 489 | 79 |
| Atorvastatin Calcium | Atorvastatin Calcium | 487 | 88 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 475 | 83 |
| Gabapentin | Gabapentin | 304 | 57 |
| Amlodipine Besylate | Amlodipine Besylate | 281 | 56 |
| Omeprazole | Omeprazole | 281 | 56 |
| Ibuprofen | Ibuprofen | 248 | 76 |
| Metformin Hcl | Metformin Hcl | 235 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 213 | 41 |
| Furosemide | Furosemide | 204 | 39 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 197 | 43 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 194 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 179 | 33 |
| Levothyroxine Sodium | Levothyroxine Sodium | 174 | 26 |
| Montelukast Sodium | Montelukast Sodium | 164 | 32 |
| Diclofenac Epolamine | Diclofenac Epolamine | 160 | 21 |
| Alcohol Pads | Alcohol Antiseptic Pads | 158 | 32 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 150 | 23 |
| Lisinopril | Lisinopril | 150 | 25 |
| Linzess | Linaclotide | 149 | 30 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 142 | 20 |
| Ozempic | Semaglutide | 138 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 135 | 41 |
| Meclizine Hcl | Meclizine Hcl | 123 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 123 | 20 |
| Mometasone Furoate | Mometasone Furoate | 119 | 19 |
| Jardiance | Empagliflozin | 114 | 20 |
| Meloxicam | Meloxicam | 113 | 24 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 112 | 19 |
| Ammonium Lactate | Ammonium Lactate | 108 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 108 | 21 |
| Labetalol Hcl | Labetalol Hcl | 107 | 16 |
| Nifedipine Er | Nifedipine | 107 | 20 |
| Halobetasol Propionate | Halobetasol Propionate | 102 | 12 |
| Ketoconazole | Ketoconazole | 100 | 19 |
| Tradjenta | Linagliptin | 100 | 18 |
| Enalapril Maleate | Enalapril Maleate | 99 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 97 | 22 |
| Doxycycline Hyclate | Doxycycline Hyclate | 95 | 66 |
| Latanoprost | Latanoprost | 95 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 94 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 91 | 23 |
| Alendronate Sodium | Alendronate Sodium | 90 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 89 | 15 |
| Farxiga | Dapagliflozin Propanediol | 89 | 16 |
| Mirtazapine | Mirtazapine | 89 | 13 |
| Januvia | Sitagliptin Phosphate | 88 | 15 |
| Carvedilol | Carvedilol | 83 | 17 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 81 | 14 |
| Losartan Potassium | Losartan Potassium | 79 | 24 |
| Metformin Er Gastric | Metformin Hcl | 79 | 15 |
| Famotidine | Famotidine | 78 | 18 |
| Ofloxacin | Ofloxacin | 75 | 31 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 73 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 17 |
| Lidocaine | Lidocaine | 71 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 69 | 13 |
| Naproxen | Naproxen | 69 | 16 |
| Trulicity | Dulaglutide | 68 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 64 | 12 |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 61 | 14 |
| Finasteride | Finasteride | 60 | 12 |
| Metformin Hcl Er | Metformin Hcl | 56 | 11 |
| Kerendia | Finerenone | 54 | suppressed |
| Memantine Hcl | Memantine Hcl | 52 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 51 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 51 | suppressed |
| Baclofen | Baclofen | 48 | 23 |
| Nitroglycerin | Nitroglycerin | 48 | suppressed |
| Atenolol | Atenolol | 47 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 47 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 45 | 15 |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 44 | suppressed |
| Irbesartan | Irbesartan | 43 | suppressed |
| Prednisone | Prednisone | 40 | 34 |
| Clotrimazole | Clotrimazole | 39 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 39 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 39 | 18 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 36 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 11 |
| Nabumetone | Nabumetone | 36 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 11 |
| Jentadueto | Linagliptin/Metformin Hcl | 33 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 31 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 28 | suppressed |
| Eliquis | Apixaban | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Vascepa | Icosapent Ethyl | 26 | suppressed |
| Meloxicam | Meloxicam, Submicronized | 25 | suppressed |
| Zileuton Er | Zileuton | 25 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | suppressed |
| Timolol Maleate | Timolol Maleate | 21 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 20 | suppressed |
| Potassium Chloride | Potassium Chloride | 20 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 20 | suppressed |
| Zafirlukast | Zafirlukast | 20 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | 13 |
| Silver Sulfadiazine | Silver Sulfadiazine | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Ciclopirox | Ciclopirox | 18 | suppressed |
| Etodolac | Etodolac | 18 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 15 |
| Tramadol Hcl | Tramadol Hcl | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 15 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Lubiprostone | Lubiprostone | 16 | suppressed |
| Simvastatin | Simvastatin | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 15 | suppressed |
| Anastrozole | Anastrozole | 15 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Desoximetasone | Desoximetasone | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 13 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 13 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Procto-Med Hc | Hydrocortisone | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Trulance | Plecanatide | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $789.50 · 34 records | Bayer Healthcare Pharmaceuticals Inc. | AIRSUPRA, BREZTRI, Dexcom G6 Transmitter, FARXIGA, Kerendia, Linzess, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error